US5234212A
(en)
*
|
1992-07-06 |
1993-08-10 |
Dutra Jr Joseph G |
Document receiving tray assembly and method of using such
|
DE69419721T2
(de)
*
|
1993-01-12 |
2000-04-27 |
Biogen Inc |
Rekombinante anti-vla4 antikörpermoleküle
|
AU687790B2
(en)
*
|
1993-02-09 |
1998-03-05 |
Biogen Idec Ma Inc. |
Treatment for insulin dependent diabetes
|
US5677291A
(en)
*
|
1993-12-10 |
1997-10-14 |
Hoechst Marion Roussel, Inc. |
Method of lowering serum cholesterol levels with 2,6-di-alkyl-4-silyl-phenols
|
KR100367948B1
(ko)
*
|
1994-01-25 |
2003-07-12 |
엘란 파마슈티칼스, 인크. |
백혈구부착분자vla-4에대한인체화된항체
|
US7435802B2
(en)
|
1994-01-25 |
2008-10-14 |
Elan Pharaceuticals, Inc. |
Humanized anti-VLA4 immunoglobulins
|
FR2724393A1
(fr)
*
|
1994-09-12 |
1996-03-15 |
Inst Nat Sante Rech Med |
Obtention d'un anticorps monoclonal recombinant humanise a partir d'un anticorps monoclonal murin, sa production en cellules d'insecte, et ses utilisations
|
US7803904B2
(en)
|
1995-09-01 |
2010-09-28 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressing and uses thereof
|
US7750137B2
(en)
|
1995-09-01 |
2010-07-06 |
Millennium Pharmaceuticals, Inc. |
Mucosal vascular addressins
|
US6551593B1
(en)
|
1995-02-10 |
2003-04-22 |
Millennium Pharmaceuticals, Inc. |
Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
|
US5795876A
(en)
*
|
1996-04-30 |
1998-08-18 |
Hoechst Marion Rousssel, Inc. |
Method of inhibiting vascular cell adhesion molecule-1 and treating chronic inflammatory diseases with 2, 6-di-alkyl-4-silyl-phenols
|
US5608095A
(en)
*
|
1996-04-30 |
1997-03-04 |
Hoechst Marion Roussel, Inc. |
Alkyl-4-silyl-phenols and esters thereof as antiatherosclerotic agents
|
US7147851B1
(en)
|
1996-08-15 |
2006-12-12 |
Millennium Pharmaceuticals, Inc. |
Humanized immunoglobulin reactive with α4β7 integrin
|
US6114572A
(en)
*
|
1996-11-20 |
2000-09-05 |
Hoechst Marion Roussel, Inc. |
Substituted phenols and thiophenols useful as antioxidant agents
|
US6121463A
(en)
*
|
1997-06-24 |
2000-09-19 |
Hoechst Marion Roussel, Inc. |
Alkyl-4-silylheterocyclic phenols and thiophenols useful as antioxidant agents
|
US6133467A
(en)
*
|
1997-06-25 |
2000-10-17 |
Hoechst Marion Roussel, Inc. |
2,6-di-t-butyl-4-[(dimethyl-4-methoxyphenylsilyl)-methyl-oxy]phenol and 2,6-di-t-butyl-4-[(dimethyl-2-methoxy-phenylsilyl)methyloxy]phenol
|
DE19741235A1
(de)
|
1997-09-18 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
DE19741873A1
(de)
*
|
1997-09-23 |
1999-03-25 |
Hoechst Marion Roussel De Gmbh |
Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
DE19751251A1
(de)
|
1997-11-19 |
1999-05-20 |
Hoechst Marion Roussel De Gmbh |
Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
|
PT1071700E
(pt)
†
|
1998-04-20 |
2010-04-23 |
Glycart Biotechnology Ag |
Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
|
DE19821483A1
(de)
|
1998-05-14 |
1999-11-18 |
Hoechst Marion Roussel De Gmbh |
Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
PL203114B1
(pl)
|
1998-09-14 |
2009-08-31 |
Regents Board Of |
Zastosowania przeciwciała przeciw VLA-4 lub jego fragmentu wiążącego antygen, przeciwciała przeciw integrynie alfa-4/beta7 lub jego fragmentu wiążącego antygen lub przeciwciała przeciw VCAM-1 lub jego fragmentu wiążącego antygen, zastosowania rozpuszczalnych polipeptydów VLA-4 lub VCAM-1, które antagonizują interakcję VLA-4/VCAM-1
|
US7618630B2
(en)
|
1998-09-14 |
2009-11-17 |
Board Of Regents, The University Of Texas System |
Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
|
ES2571230T3
(es)
|
1999-04-09 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para controlar la actividad de una molécula inmunofuncional
|
IL145898A0
(en)
|
1999-04-22 |
2002-07-25 |
Biogen Inc |
Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
|
DE19922462A1
(de)
|
1999-05-17 |
2000-11-23 |
Aventis Pharma Gmbh |
Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
EA011384B1
(ru)
|
1999-06-01 |
2009-02-27 |
Байоджен Айдек Ма Инк. |
Способ лечения воспалительного заболевания
|
DK1214091T3
(da)
*
|
1999-09-14 |
2006-08-28 |
Biogen Idec Inc |
Terapier til kronisk nyresvigt under anvendelse af én eller flere integrinantagonister
|
ES2415708T3
(es)
|
1999-12-16 |
2013-07-26 |
Biogen Idec Ma Inc. |
Métodos de tratamiento de la lesión isquémica o hemorrágica del sistema nervioso central mediante el uso de antagonistas anti-integrina alfa4
|
US20060115473A1
(en)
*
|
2000-12-14 |
2006-06-01 |
Biogen Idec Ma Inc., A Massachusetts Corporation |
Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
|
JP3459609B2
(ja)
*
|
2000-03-17 |
2003-10-20 |
三洋電機株式会社 |
ライトキャッシュ回路、ライトキャッシュ回路を備えた記録装置、およびライトキャッシュ方法
|
AU2016204535C1
(en)
*
|
2000-04-12 |
2017-02-23 |
Laboratoire Français Du Fractionnement Et Des Biotechnologies |
Anti-D monoclonal antibodies
|
FR2807767B1
(fr)
|
2000-04-12 |
2005-01-14 |
Lab Francais Du Fractionnement |
Anticorps monoclonaux anti-d
|
US6946292B2
(en)
|
2000-10-06 |
2005-09-20 |
Kyowa Hakko Kogyo Co., Ltd. |
Cells producing antibody compositions with increased antibody dependent cytotoxic activity
|
DE10111877A1
(de)
|
2001-03-10 |
2002-09-12 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
|
UA83791C2
(ru)
|
2001-04-13 |
2008-08-26 |
Байоджен Айдек Ма Инк. |
Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
|
DE10137595A1
(de)
|
2001-08-01 |
2003-02-13 |
Aventis Pharma Gmbh |
Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
|
CA2838062C
(fr)
|
2001-08-03 |
2015-12-22 |
Roche Glycart Ag |
Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
|
WO2003070709A1
(fr)
|
2002-02-20 |
2003-08-28 |
Ajinomoto Co.,Inc. |
Nouveau derive de phenylalanine
|
AU2003213231A1
(en)
|
2002-02-25 |
2003-09-09 |
Elan Pharmaceuticals, Inc. |
Administration of agents for the treatment of inflammation
|
US7576101B2
(en)
|
2003-01-24 |
2009-08-18 |
Elan Pharmaceuticals, Inc. |
Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
|
CA2522207A1
(fr)
*
|
2003-04-14 |
2004-10-28 |
Board Of Regents, The University Of Texas System |
Procedes destines a la production ex vivo sans hybridomes d'anticorps polyclonaux ou monoclonaux et a la generation de populations de cellules immortalisees
|
US7485291B2
(en)
*
|
2003-06-03 |
2009-02-03 |
Cell Genesys, Inc. |
Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
|
US20050136035A1
(en)
*
|
2003-06-03 |
2005-06-23 |
Derek Ko |
Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
|
WO2005017149A1
(fr)
*
|
2003-06-03 |
2005-02-24 |
Cell Genesys, Inc. |
Compositions et methodes pour une expression amelioree de polypeptides recombinants a partir d'un vecteur unique, faisant appel a un site de clivage peptidique
|
US7691810B2
(en)
|
2003-10-09 |
2010-04-06 |
Kyowa Hakko Kirin Co., Ltd |
Method of producing recombinant antithrombin III composition
|
US7496938B2
(en)
*
|
2003-11-24 |
2009-02-24 |
Sabic Innovative Plastics Ip B.V. |
Media drive with a luminescence detector and methods of detecting an authentic article
|
BRPI0418026A
(pt)
|
2003-12-22 |
2007-04-17 |
Ajinomoto Kk |
derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
|
EP1718310A4
(fr)
*
|
2004-02-06 |
2009-05-06 |
Elan Pharm Inc |
Methodes et compositions de traitement de tumeurs et de maladie metastatique
|
US7419666B1
(en)
|
2004-02-23 |
2008-09-02 |
Massachusetts Eye And Ear Infirmary |
Treatment of ocular disorders
|
JP2007532681A
(ja)
*
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
B細胞の枯渇を増大させる方法
|
US7714119B2
(en)
*
|
2004-07-13 |
2010-05-11 |
Biosante Pharmaceuticals, Inc. |
AAV vector compositions and methods for enhanced expression of immunoglobulins using the same
|
CA2478458A1
(fr)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Traitement de la sclerose en plaques pediatrique
|
GB0420771D0
(en)
*
|
2004-09-17 |
2004-10-20 |
Randox Lab Ltd |
Antibody
|
CN103169965A
(zh)
*
|
2004-11-19 |
2013-06-26 |
比奥根艾迪克Ma公司 |
治疗多发性硬化
|
NZ556105A
(en)
*
|
2004-12-03 |
2009-12-24 |
Biogen Idec Inc |
Delaying or preventing onset of multiple sclerosis
|
EP2332408B1
(fr)
|
2005-02-17 |
2013-11-13 |
Biogen Idec MA Inc. |
Traitement de troubles neurologiques
|
BRPI0608254A2
(pt)
|
2005-03-02 |
2009-12-08 |
Biogen Idec Inc |
anticorpos kim-1 para o tratamento de condições mediadas por th2
|
AU2006220709B2
(en)
*
|
2005-03-04 |
2012-09-06 |
Biogen Ma Inc. |
Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
|
WO2006105511A1
(fr)
|
2005-03-31 |
2006-10-05 |
The General Hospital Corporation |
Activite de surveillance et de modulation de hgf/hgfr
|
CN101351710B
(zh)
|
2005-04-04 |
2013-06-05 |
生物基因Idecma公司 |
评价对治疗性蛋白质的免疫应答的方法和产品
|
US7632509B2
(en)
*
|
2005-07-19 |
2009-12-15 |
Biosante Pharmaceuticals, Inc. |
Methods to express recombinant proteins from lentiviral vectors
|
EP1910550A4
(fr)
|
2005-07-21 |
2009-11-04 |
Abbott Lab |
Expression multigenique comprenant des constructions sorf et methodes faisant appel a des polyproteines, a des pro-proteines, et a une proteolysis
|
EP2272497B1
(fr)
|
2006-01-18 |
2012-10-03 |
The General Hospital Corporation |
Procédés pour augmenter la fonction lymphatique
|
CA2641513C
(fr)
|
2006-02-28 |
2021-09-21 |
Elan Pharmaceuticals, Inc. |
Methodes pour traiter des maladies inflammatoires et auto-immunes avec du natalizumab
|
WO2007100763A2
(fr)
*
|
2006-02-28 |
2007-09-07 |
Elan Pharmaceuticals, Inc. |
Méthodes pour traiter des maladies inflammatoires et auto-immunes avec des composés inhibiteurs alpha-4
|
KR20080104343A
(ko)
|
2006-03-03 |
2008-12-02 |
엘란 파마슈티칼스, 인크. |
나탈리주마브로 염증 및 자가면역 질환을 치료하는 방법
|
US9868961B2
(en)
|
2006-03-30 |
2018-01-16 |
The Regents Of The University Of California |
Methods and compositions for localized secretion of anti-CTLA-4 antibodies
|
US7919079B2
(en)
*
|
2006-03-31 |
2011-04-05 |
Biosante Pharmaceuticals, Inc. |
Cancer immunotherapy compositions and methods of use
|
US20070292922A1
(en)
*
|
2006-03-31 |
2007-12-20 |
Cell Genesys, Inc. |
Regulated expression of recombinant proteins from adeno-associated viral vectors
|
DK2034830T3
(da)
|
2006-05-25 |
2014-10-27 |
Biogen Idec Inc |
Anti-vla-1-antistof til behandling af slagtilfælde
|
US8288110B2
(en)
*
|
2006-12-04 |
2012-10-16 |
Perkinelmer Health Sciences, Inc. |
Biomarkers for detecting cancer
|
WO2008103378A2
(fr)
|
2007-02-20 |
2008-08-28 |
Merrimack Pharmaceuticals, Inc. |
Méthodes de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine
|
MX2009013593A
(es)
|
2007-06-14 |
2010-01-20 |
Biogen Idec Inc |
Formulaciones de anticuerpos.
|
EP2200611A4
(fr)
|
2007-09-14 |
2010-09-22 |
Biogen Idec Inc |
Compositions et procédés de traitement de la leucoencéphalopathie multifocale progressive (lemp)
|
EP2085407A1
(fr)
|
2008-02-04 |
2009-08-05 |
Sahltech I Göteborg AB |
Traitement de purpura thrombopénique idiopathique
|
CN102057054B
(zh)
|
2008-04-11 |
2015-06-10 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
JP2011523560A
(ja)
|
2008-06-02 |
2011-08-18 |
ダナ−ファーバー キャンサー インスティテュート インク. |
Xbp1ペプチド、cd138ペプチドおよびcs1ペプチド
|
EP2315779A2
(fr)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprenant des anticorps anti-lingo ou leurs fragments
|
JP5677972B2
(ja)
|
2008-11-18 |
2015-02-25 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
MX2011010971A
(es)
*
|
2009-04-17 |
2012-01-19 |
Biogen Idec Inc |
Composiciones y metodos para tratar leucemia mielogena aguda.
|
EP2467159A1
(fr)
|
2009-08-20 |
2012-06-27 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Vla-4 en tant que biomarqueur pour le pronostic et le ciblage pour thérapie dans la dystrophie musculaire de duchenne
|
EP2485762B1
(fr)
*
|
2009-10-11 |
2017-12-13 |
Biogen MA Inc. |
Tests associés à un anti-vla-4
|
BR112012009638A2
(pt)
*
|
2009-10-23 |
2016-11-29 |
Hanwha Chemical Corp |
anticorpo recombinante monoclonal humano que se liga especificamente a vcam-1 e inibe a adesão e a transmigração entre leucócitos e células endoteliais
|
AU2010313395A1
(en)
|
2009-10-30 |
2012-05-10 |
Abbvie Inc. |
sORF constructs and multiple gene expression
|
AU2011203815B2
(en)
|
2010-01-11 |
2015-11-26 |
Biogen Ma Inc. |
Assay for JC virus antibodies
|
US11287423B2
(en)
|
2010-01-11 |
2022-03-29 |
Biogen Ma Inc. |
Assay for JC virus antibodies
|
AU2011239512B2
(en)
|
2010-04-16 |
2016-01-21 |
Biogen Ma Inc. |
Anti-VLA-4 antibodies
|
EP3470421B9
(fr)
|
2010-07-29 |
2023-10-04 |
Buzzard Pharmaceuticals AB |
Antagonistes chimériques du récepteur d'il-1 type i
|
CA2807552A1
(fr)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Acides nucleiques modifies et leurs procedes d'utilisation
|
WO2012027494A1
(fr)
|
2010-08-24 |
2012-03-01 |
Regents Of The University Of Minnesota |
Réactifs bispécifiques de ciblage
|
CN104531812A
(zh)
|
2010-10-01 |
2015-04-22 |
现代治疗公司 |
设计核酸及其使用方法
|
LT3326645T
(lt)
|
2010-10-25 |
2020-08-10 |
Biogen Ma Inc. |
Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai
|
WO2012103240A2
(fr)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Agents de liaison à un récepteur
|
HUE037095T2
(hu)
|
2011-03-09 |
2018-08-28 |
Cell Signaling Technology Inc |
Eljárások és reagensek monoklonális ellenanyagok elõállítására
|
WO2012135805A2
(fr)
|
2011-03-31 |
2012-10-04 |
modeRNA Therapeutics |
Administration et formulation d'acides nucléiques génétiquement modifiés
|
UY34054A
(es)
|
2011-05-02 |
2012-11-30 |
Millennium Pharm Inc |
FORMULACIÓN PARA ANTICUERPO ANTI-a(alfa)4B(Beta)7
|
UA116189C2
(uk)
|
2011-05-02 |
2018-02-26 |
Мілленніум Фармасьютікалз, Інк. |
КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
RU2707251C2
(ru)
|
2011-10-03 |
2019-11-25 |
Модерна Терапьютикс, Инк. |
Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
|
CA2850885A1
(fr)
|
2011-10-17 |
2013-04-25 |
Westfaelische Wilhelms-Universitaet Muenster |
Evaluation du risque de lemp et methodes associees
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
WO2013091903A1
(fr)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anticorps anti-canal crac
|
US10160808B2
(en)
|
2012-02-16 |
2018-12-25 |
Santarus, Inc. |
Anti-VLA1 (CD49A) antibody pharmaceutical compositions
|
EP3575311A1
(fr)
|
2012-03-20 |
2019-12-04 |
Biogen MA Inc. |
Anticorps neutralisant le virus jcv
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
EP2833892A4
(fr)
|
2012-04-02 |
2016-07-20 |
Moderna Therapeutics Inc |
Polynucléotides modifiés destinés à la production de protéines et de peptides associés à l'oncologie
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
EP2845134A1
(fr)
|
2012-04-20 |
2015-03-11 |
Biogen Idec MA Inc. |
Paramètres cognitifs composites et leur utilisation pour le diagnostic de la sclérose en plaques
|
CN104470541A
(zh)
|
2012-05-14 |
2015-03-25 |
比奥根艾迪克Ma公司 |
用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
|
EP2883177A1
(fr)
|
2012-08-13 |
2015-06-17 |
Biogen Idec MA Inc. |
Paramètres de progression de la maladie et leurs utilisations dans l'évaluation de la sclérose en plaques
|
WO2014036520A1
(fr)
|
2012-08-30 |
2014-03-06 |
Merrimack Pharmaceuticals, Inc. |
Polythérapies comprenant des agents anti-erbb3
|
EP3750560A3
(fr)
|
2012-10-09 |
2021-03-24 |
Biogen MA Inc. |
Polythérapies et utilisations pour le traitement de troubles de démyélinisation
|
JP6374392B2
(ja)
|
2012-11-05 |
2018-08-15 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Xbp1、cd138およびcs1ペプチド、該ペプチドを含有する薬学的組成物、ならびにかかるペプチドおよび組成物を使用する方法
|
JP6144355B2
(ja)
|
2012-11-26 |
2017-06-07 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
化学修飾mRNA
|
RU2015143521A
(ru)
|
2013-03-13 |
2017-04-19 |
Илэвэн Байотерапьютикс, Инк. |
Лекарственные формы химерных цитокинов для глазной доставки
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
WO2014193804A1
(fr)
|
2013-05-28 |
2014-12-04 |
Biogen Idec Ma Inc. |
Méthodes d'évaluation de risque de développement d'une lemp
|
EP3043775B1
(fr)
|
2013-09-11 |
2020-11-04 |
Eagle Biologics, Inc. |
Formulations de protéines liquides contenant des agents abaissant la viscosité
|
WO2015048744A2
(fr)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucléotides codant des polypeptides de modulation immunitaire
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
WO2015063604A2
(fr)
|
2013-11-01 |
2015-05-07 |
Imberti Luisa |
Biomarqueurs prédictifs de la réponse thérapeutique à ifnβ et utilisations de ceux-ci
|
US20170216434A1
(en)
*
|
2014-08-05 |
2017-08-03 |
Wayne State University |
Compositions and methods for treatment of sickle cell disease
|
KR102497368B1
(ko)
|
2014-10-01 |
2023-02-10 |
이글 바이올로직스 인코포레이티드 |
점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형
|
US10435467B2
(en)
|
2015-01-08 |
2019-10-08 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
EP3302465A1
(fr)
|
2015-06-05 |
2018-04-11 |
Vertex Pharmaceuticals Incorporated |
Triazoles pour le traitement de maladies liées à la démyélinisation
|
AU2017297404A1
(en)
|
2016-07-13 |
2019-01-24 |
Biogen Ma Inc. |
Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
WO2018045162A1
(fr)
|
2016-09-01 |
2018-03-08 |
Biogen Ma Inc. |
Biomarqueurs prédictifs de la sclérose en plaques progressive primaire et leurs utilisations
|
WO2018106646A1
(fr)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Aminotriazoles pour traiter des maladies démyélinisantes
|
WO2018106641A1
(fr)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles pour le traitement de maladies démyélinisantes
|
WO2018106643A1
(fr)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Azoles hétérocycliques pour le traitement de maladies de démyélinisation
|
WO2018140510A1
(fr)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Composition et méthodes de traitement d'un accident vasculaire cérébral et d'autres troubles du snc
|
CA3063324A1
(fr)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
Formulations de proteines a haute concentration ayant une viscosite reduite
|
WO2019236417A1
(fr)
|
2018-06-04 |
2019-12-12 |
Biogen Ma Inc. |
Anticorps anti-vla-4 ayant une fonction effectrice réduite
|
CA3133072A1
(fr)
|
2019-03-11 |
2020-09-17 |
Biogen Ma Inc. |
Compositions pharmaceutiques contenant des anticorps anti-lingo-1
|
US11339061B2
(en)
|
2020-02-05 |
2022-05-24 |
Garron M. Hobson |
Solar water pasteurizer
|
KR20230013258A
(ko)
|
2020-05-19 |
2023-01-26 |
얀센 바이오테크 인코포레이티드 |
T 세포 재유도 치료제 및 vla-4 부착 경로 억제제를 포함하는 조성물
|
EP4340942A1
(fr)
|
2021-05-18 |
2024-03-27 |
Janssen Biotech, Inc. |
Compositions comprenant un agent thérapeutique de redirection des lymphocytes t et un agent thérapeutique anti-cd44
|